Viral quasispecies

PLoS Genet. 2019 Oct 17;15(10):e1008271. doi: 10.1371/journal.pgen.1008271. eCollection 2019 Oct.

Abstract

Viral quasispecies refers to a population structure that consists of extremely large numbers of variant genomes, termed mutant spectra, mutant swarms or mutant clouds. Fueled by high mutation rates, mutants arise continually, and they change in relative frequency as viral replication proceeds. The term quasispecies was adopted from a theory of the origin of life in which primitive replicons) consisted of mutant distributions, as found experimentally with present day RNA viruses. The theory provided a new definition of wild type, and a conceptual framework for the interpretation of the adaptive potential of RNA viruses that contrasted with classical studies based on consensus sequences. Standard clonal analyses and deep sequencing methodologies have confirmed the presence of myriads of mutant genomes in viral populations, and their participation in adaptive processes. The quasispecies concept applies to any biological entity, but its impact is more evident when the genome size is limited and the mutation rate is high. This is the case of the RNA viruses, ubiquitous in our biosphere, and that comprise many important pathogens. In virology, quasispecies are defined as complex distributions of closely related variant genomes subjected to genetic variation, competition and selection, and that may act as a unit of selection. Despite being an integral part of their replication, high mutation rates have an upper limit compatible with inheritable information. Crossing such a limit leads to RNA virus extinction, a transition that is the basis of an antiviral design termed lethal mutagenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Evolution, Molecular
  • High-Throughput Nucleotide Sequencing
  • Mutation Rate
  • Origin of Life
  • Quasispecies*
  • RNA Viruses / genetics
  • RNA Viruses / immunology
  • RNA Viruses / physiology*
  • Viral Vaccines / immunology
  • Virus Replication

Substances

  • Viral Vaccines

Grants and funding

Work by ED and CP was supported by grants BFU2011-23604, SAF2014-52400-R, SAF2017-87846-R and BFU2017-91384-EXP, from the Spanish Ministerio de Economía y Competitividad (MINECO) (www.mineco.gob.es) and S2013/ABI-2906 (PLATESA from Comunidad de Madrid/FEDER) (http://platesa-es.weebly.com). CIBERehd (Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas) (www.ciberisciii.es) is funded by Instituto de Salud Carlos III. C.P. is supported by the Miguel Servet program of the Instituto de Salud Carlos III (CP14/00121) cofinanced by the European Regional Development Fund (ERDF). Institutional grants from the Fundación Ramón Areces and Banco Santander to the CBMSO are also acknowledged. The funders had no role in the preparation of the article.